Background Ketamine and esketamine offer a novel approach in the pharmacological
treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the …

Introduction and aims Treatment-resistant depression (TRD) occurs when at least two
different antidepressants, taken at the right dosage, for adequate period of time and with …

This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

Up to 20% of depressed patients demonstrate treatment resistance to one or more adequate
antidepressant trials, resulting in a disproportionately high burden of illness. Ketamine is a …

Background Recent studies demonstrating a rapid, robust improvement in treatment
resistant depression (TRD) following a single sub-anesthetic infusion of ketamine have …

Introduction Ketamine's efficacy in depressive disorders has been established in several
controlled trials. The aim of the present study was to determine whether or not ketamine …

Objectives We examined the feasibility of a high-dose, 96-h infusion of ketamine in treatment-
resistant depression. Methods Ten participants were randomised to receive a 96-h ketamine …

Currently available drugs for unipolar major depressive disorder (MDD), which target
monoaminergic systems, have a delayed onset of action andsignificant limitations in …

Background: Evidence suggests that clinical markers, such as comorbid anxiety, body
weight, and others can assist in predicting response to low-dose ketamine infusion in …

Strong evidence supports the rapid, although temporary, antidepressant effects of a single
intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and …